Literature DB >> 14742214

Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Augustine F B Cheng1, Wing W Yew, Edward W C Chan, Miu L Chin, Mamie M M Hui, Raphael C Y Chan.   

Abstract

A new strategy known as multiplex PCR amplimer conformation was developed for detection of mutation in the gyrA gene of 138 clinical isolates of Mycobacterium tuberculosis. The method generated a single-stranded and heteroduplex DNA banding pattern of multiplex PCR amplimers of the region of interest that was extremely sensitive to specific mutations, thus enabling much more sensitive and reliable mutation analysis compared to the standard single-stranded conformation polymorphism technique. The genetic profiles of the gyrA gene of the 138 isolates as detected by MPAC were confirmed by nucleotide sequencing and were found to correlate strongly with the in vitro susceptibilities of the mutant strains to six fluoroquinolones (ofloxacin, levofloxacin, sparfloxacin, moxifloxacin, gatifloxacin, and sitafloxacin). All 32 isolates that contained gyrA mutations exhibited cross-resistance to the six fluoroquinolones (ofloxacin MIC for 90% of strains > 16 mg/liter), although moxifloxacin, gatifloxacin, and sitafloxacin (MIC for 90% of strains </= 4 mg/liter) were apparently more active than ofloxacin, levofloxacin, and sparfloxacin (MIC for 90% of strains >/==" BORDER="0"> 16 mg/liter). All gyrA mutations were clustered in codons 90, 91, and 94, and aspartic acid 94 was most frequently mutated. Twenty-three isolates without gyrA mutations were also found to exhibit reduced susceptibility to ofloxacin (MIC for 90% of strains = 4 mg/liter), but largely remained susceptible to other drugs (MIC for 90% of strains </= 1 mg/liter). Another 83 isolates without mutations were fully susceptible to all six fluoroquinolones (ofloxacin MIC for 90% of strains = 1 mg/liter). In conclusion, high-level phenotypic resistance to fluoroquinolones among M. tuberculosis clinical isolates, which appears to be predominantly due to gyrA mutations, may be readily detected by genotyping techniques such as multiplex PCR amplimer conformation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742214      PMCID: PMC321542          DOI: 10.1128/AAC.48.2.596-601.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

Authors:  S L Moghazeh; X Pan; T Arain; C K Stover; J M Musser; B N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

2.  Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis.

Authors:  A Meier; P Sander; K J Schaper; M Scholz; E C Böttger
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis.

Authors:  C Xu; B N Kreiswirth; S Sreevatsan; J M Musser; K Drlica
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

Authors:  T E Renau; J W Gage; J A Dever; G E Roland; E T Joannides; M A Shapiro; J P Sanchez; S J Gracheck; J M Domagala; M R Jacobs; R C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh
Journal:  Curr Microbiol       Date:  1996-09       Impact factor: 2.188

6.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.

Authors:  H Saito; H Tomioka; K Sato; S Dekio
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors:  T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

Authors:  H Saito; K Sato; H Tomioka; S Dekio
Journal:  Tuber Lung Dis       Date:  1995-10

10.  Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.

Authors:  A Kitamura; K Hoshino; Y Kimura; I Hayakawa; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  32 in total

Review 1.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

2.  Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Authors:  Florence Brossier; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

3.  Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India.

Authors:  Kanchan Ajbani; Camilla Rodrigues; Shubhada Shenai; Ajita Mehta
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

4.  Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Authors:  Alexandra Aubry; Nicolas Veziris; Emmanuelle Cambau; Chantal Truffot-Pernot; Vincent Jarlier; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 5.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

6.  Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.

Authors:  Stéphanie Matrat; Nicolas Veziris; Claudine Mayer; Vincent Jarlier; Chantal Truffot-Pernot; Juliette Camuset; Elisabeth Bouvet; Emmanuelle Cambau; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

7.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

8.  Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase.

Authors:  Rupesh Kumar; Bhavani Shankar Madhumathi; Valakunja Nagaraja
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

9.  Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Authors:  Aurélie Fillion; Alexandra Aubry; Florence Brossier; Aurélie Chauffour; Vincent Jarlier; Nicolas Veziris
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

10.  Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing.

Authors:  Ruiru Shi; Jianyuan Zhang; Chuanyou Li; Yuko Kazumi; Isamu Sugawara
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.